McKesson Corporation research snapshot
MCK AI stock analysis currently reads McKesson Corporation as a high-scale healthcare services and pharmaceutical distribution business with strong cash flow, persistent share repurchases, specialty oncology exposure, and low but durable operating margins. At the July 8, 2026 data cutoff, MCK traded near $807.33 with market capitalization near $94.52 billion. The AI analysis score is constructive for business quality, cash conversion, and execution, but the MCK AI stock forecast uses scenarios rather than a single target because drug distribution margins, customer concentration, opioid liabilities, reimbursement pressure, and valuation multiples can shift quickly. This page is informational research and not investment advice.
Current price
$807.33
Market cap
$94.52 billion
AI score
74 / 100
Rating
High-quality healthcare distribution compounder with strong cash generation, but valuation now depends on sustained specialty growth and customer concentration discipline
Trend status
Short-term rebound above key EMAs, still below the March 2026 52-week high and not a clean long-term breakout
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | McKesson moves pharmaceuticals, medical-surgical supplies, oncology services, prescription technology, and related healthcare services through a national and increasingly specialty-oriented platform. | High |
| Moat | The moat comes from scale, distribution density, procurement relationships, regulated infrastructure, customer workflow integration, specialty oncology reach, and technology that helps pharmacies and providers manage access and reimbursement. | Medium-high |
| Management | Brian Tyler has led McKesson since 2019 and became board chair in May 2026. Capital allocation has emphasized divestitures, specialty acquisitions, dividends, and buybacks, but CEO ownership is modest relative to company value. | Medium |
| Financial trend | FY2026 revenue was $403.43 billion, net income attributable to McKesson was $4.76 billion, adjusted EPS was $39.11, operating cash flow was $6.2 billion, and free cash flow was $5.4 billion. | High |
| Valuation | At $807.33, financial_rigor.py calculates about 21.04x GAAP EPS, 18.52x free cash flow per share, a 5.40% FCF yield, and a 0.41% dividend yield. Book value is negative because of treasury shares. | High |
| Technical trend | MCK recovered above short-term EMA zones near $768 to $783 but remained far below the $999.00 52-week high. Barchart still showed several longer-term moving-average signals as sell, so trend quality is mixed. | Medium |
| Risk level | Main risks are low distribution margins, customer concentration, opioid liabilities, reimbursement pressure, generic pricing changes, GLP-1 supply and demand volatility, cyber risk, execution risk in medical-surgical separation, and multiple compression. | Medium-high |
| AI confidence | High for reported financials and calculations. Medium for forecast because healthcare distributors can rerate on regulation, customer contracts, drug mix, litigation, and capital allocation. | High data confidence |
| Investment certainty | Medium certainty. McKesson has a durable role in the healthcare supply chain, but the current thesis requires continued specialty growth, cash conversion, contract discipline, and controlled legal and policy risk. | Medium |
MCK AI stock forecast
The MCK AI stock forecast uses scenario math around the $807.33 quote and $39.11 adjusted EPS. A three-year framework audited with financial_rigor.py produced a bullish value near $1,465, a base value near $1,185, and a bearish value near $699 before dividends. The range is wide by design because McKesson combines defensive healthcare demand with thin margins, customer concentration, litigation liabilities, and valuation sensitivity.
$1,400 to $1,470
More likely if adjusted EPS compounds near the high end of management long-term targets, oncology and specialty services keep growing, medical-surgical separation improves focus, free cash flow funds buybacks, and the market values MCK near 24x earnings.
$1,130 to $1,200
More likely if adjusted EPS grows near 13%, distribution margins stay stable, cash conversion remains strong, opioid cash payments are manageable, and investors value MCK near 21x earnings.
$675 to $710
More likely if customer concentration pressure, reimbursement changes, drug mix, GLP-1 supply issues, litigation payments, separation execution, or market risk appetite push EPS growth toward mid single digits and the multiple toward 15x.
MCK AI technical analysis
MCK AI technical analysis was mixed as of the July 8, 2026 data cutoff. Google Finance and MarketWatch showed the stock near $807.33 after a sharp rebound, with a 52-week high of $999.00 and a 52-week low near $637.00. Financhill listed 8-day, 20-day, and 50-day EMA zones near $770.98, $768.47, and $783.12, while Barchart still flagged longer-term moving-average conditions as weak. The setup is a rebound and repair pattern, not a confirmed fresh long-term breakout.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $807.33 | MarketWatch reported the July 7, 2026 close at $807.33, and Google Finance showed market cap near $94.52 billion at the July 8, 2026 cutoff. |
| Near support | $783 to $807 | The first support zone spans the 50-day EMA snapshot near $783.12 and the recent rebound close near $807.33. |
| Secondary support | $768 to $771 | Financhill listed 20-day and 8-day EMA snapshots around $768.47 and $770.98, making this a lower short-term trend zone. |
| Near resistance | $812 to $825 | Google Finance showed an intraday high near $811.91, and late-April trading near $822.63 marks the next repair area. |
| Major resistance | $999 | Google Finance, MarketWatch, and McKesson investor relations listed the 52-week high at $999.00. |
| 50-day moving average | $783.12 EMA snapshot | Financhill showed price slightly above the 50-day exponential moving average, a short-term positive signal. |
| 200-day moving average | Long-term signal still weak | Barchart listed 200-day moving-average signals as sell, so the longer-term trend needed more repair. |
| Momentum | Rebound, not breakout | The stock rebounded from late-June weakness but remained about 19% below the March 2026 high. |
| Volume | About 1.2M average shares | MarketWatch cited 50-day average volume near 1.2 million shares around the July 2026 rebound. |
| Invalidation | Close below $783, then $768 | A close below the 50-day EMA area would weaken the rebound. A break below the 20-day and 8-day EMA zone would signal failed short-term repair. |
MCK AI trading strategy
The MCK AI trading strategy is a rules-based framework for a healthcare distribution stock with defensive demand but thin margins and policy risk. It is not personalized advice and should be paired with live chart data, earnings releases, customer contract updates, legal reserve changes, and clear invalidation levels.
Watch for MCK to hold above the $783 to $807 support zone and then clear $812 to $825 on above-average volume, with confirmation from healthcare distribution peers and no negative contract, reimbursement, or litigation headlines.
A failed move back below the 50-day EMA area should invalidate the near-term trend setup.
If MCK pulls back toward $783 or $768 while FY2027 adjusted EPS guidance, free cash flow, customer contracts, and opioid cash timing remain intact, compare the drawdown with the long-term distribution and specialty services thesis.
Do not treat defensive healthcare demand as a substitute for risk control. Distributor margins are thin, and valuation can compress quickly.
Track North American Pharmaceutical revenue, Oncology & Multispecialty growth, Prescription Technology Solutions margins, Medical-Surgical separation milestones, free cash flow, share repurchases, opioid liabilities, and top-customer exposure.
Reduce confidence if operating profit fails to grow with revenue, free cash flow falls materially below earnings, customer concentration worsens, or legal and policy risks consume more cash than expected.
Investment research summary
McKesson gets paid to make the healthcare supply chain work: it sources, distributes, finances, tracks, and supports medicines and medical products for pharmacies, providers, manufacturers, payers, and patients.
The moat is built from scale logistics, regulated distribution licenses, purchasing reach, dense customer relationships, workflow software, specialty oncology networks, and the difficulty of replacing a national distributor without disrupting patient care.
The thesis fails if a major customer reprices or leaves, distribution margins compress, opioid or tax liabilities absorb cash, GLP-1 supply volatility hurts revenue mix, cyber disruption damages trust, or medical-surgical separation distracts management.
Brian Tyler has spent more than 25 years at McKesson, became CEO in 2019, and became chair in May 2026. The record shows disciplined buybacks and portfolio moves, while modest direct CEO ownership keeps alignment at medium rather than high.
Healthcare demand, specialty medicine, oncology care, biologics, patient access tools, and pharmacy workflow complexity support long-term relevance, but public policy and reimbursement rules decide how much economics stay with distributors.
At about 21.04x GAAP EPS and 18.52x free cash flow per share, MCK is priced as a quality compounder. Margin of safety improves if the stock pulls back while free cash flow, customer retention, specialty growth, and legal reserves stay controlled.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $807.33 | MarketWatch MCK July 7, 2026 close | July 8, 2026 |
| Market capitalization | $94.52 billion | Google Finance MCK quote | July 8, 2026 |
| Shares outstanding | 117.08 million | Google Finance MCK quote | July 8, 2026 |
| FY2026 revenue | $403.43 billion | McKesson FY2026 Form 10-K | July 8, 2026 |
| FY2026 net income attributable to McKesson | $4.76 billion | McKesson FY2026 Form 10-K | July 8, 2026 |
| FY2026 adjusted EPS | $39.11 | McKesson FY2026 Q4 earnings release | July 8, 2026 |
| FY2026 free cash flow | $5.4 billion | McKesson FY2026 Q4 earnings release | July 8, 2026 |
| Cash and equivalents | $3.98 billion | McKesson FY2026 Form 10-K | July 8, 2026 |
| Debt | $6.53 billion current plus long-term debt | McKesson FY2026 Form 10-K | July 8, 2026 |
| 52-week range | $637.00 to $999.00 | McKesson investor relations stock information | July 8, 2026 |
| CEO and chair | Brian S. Tyler | McKesson board biography | July 8, 2026 |
| Fiscal 2027 adjusted EPS guidance | $43.80 to $44.60 | McKesson FY2026 Q4 earnings release | July 8, 2026 |
This MCK AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, a price guarantee, or a promise of return. Forecast scenarios are based on available public data as of July 8, 2026 and may be wrong if McKesson fundamentals, technical conditions, regulation, litigation, customer contracts, or market valuation change.
